| Continued robust biotech funding and increased R&D spending by pharmaceutical companies are expected to drive sustained demand for early-stage discovery, safety assessment, and clinical development services. | Ongoing through Q4 2026 and beyond | 2026-09-22 | 2026-12-31 | This macro trend directly impacts the core business of CROs and life sciences tools providers. A robust funding environment for small and mid-sized biotechs, coupled with large pharma outsourcing, fuels the pipeline for drug discovery and development, benefiting all theme constituents. Charles River Laboratories specifically notes trailing 12-month funding nearing $100 billion. | Theme | theme_composer | CRL, TMO, MEDP, LONN.SW | 4 | 0.0077 | 1.18 | 0.92 | | 1.0 | 0.836 | 2026-09-22 | False | 1 | 0.6681 | 72.5318 | | Theme composer | | |
| Lonza Group AG is expected to finalize the divestment of its Capsules & Health Ingredients (CHI) business, completing its transformation into a pure-play CDMO. | Before year-end 2026 | 2026-09-22 | 2026-12-31 | This divestment is crucial for Lonza as it sharpens its strategic focus on core CDMO growth opportunities, simplifies its portfolio, and allows for disciplined capital allocation. A successful and timely closing will reinforce investor confidence in Lonza's strategic direction and operational efficiency. | Ticker | theme_composer | LONN.SW | 1 | 0.0007 | 1.18 | 0.92 | | 1.0 | 0.0785 | 2026-09-22 | False | 1 | 0.0082 | 0.8879 | | Theme composer | | |
| Charles River Laboratories expects a significant positive impact on its Discovery and Safety Assessment (DSA) segment's operating margin in Q4 2026 due to lower non-human primate (NHP) sourcing costs. | Q4 2026 | 2026-10-01 | 2026-12-31 | This is a key driver for CRL's profitability. The realization of lower NHP sourcing costs, primarily from recent acquisitions, is anticipated to lead to the highest DSA operating margin in Q4, directly impacting overall company earnings and validating the benefits of strategic supply chain control. | Ticker | theme_composer | CRL | 1 | 0.0002 | 1.18 | 1.0 | | 1.0 | 0.0247 | 2026-09-22 | False | 1 | 0.0024 | 0.2789 | | Theme composer | | |
| Lower non-human primate (NHP) sourcing costs from the K.F. Cambodia acquisition are expected to largely benefit the Discovery and Safety Assessment (DSA) operating margin. | largely benefit the fourth quarter | 2026-10-01 | 2026-12-31 | This will drive significant margin contribution in the DSA segment, improving profitability and competitive advantage due to more reliable NHP supply. | Ticker | | | | | | | | | | | | | | | earnings_transcript | CRL (ticker) | CRL_bc24e2af | 2026-08-05 |
| Management update on the durable fix and trajectory for Sterilization and Disinfection Control (SDC) delivery reliability. | when we give full year guidance at our next earnings call in November | 2026-11-01 | 2026-11-30 | Resolution of SDC's operational issues is crucial for recovering revenue and maintaining customer loyalty in a core segment. Demonstrating significant progress would be bullish. | Ticker | | | | | | | | | | | | | | | earnings_transcript | MLAB (ticker) | MLAB_9039e230 | 2026-08-10 |
| Mesa Laboratories will provide full-year fiscal 2027 guidance alongside first half results. | in the fall at our next earnings call when I put full year guidance in front of you alongside first half results | 2026-11-01 | 2026-11-30 | This guidance will offer a comprehensive financial outlook for the current fiscal year, providing critical information for investors regarding the company's expected performance and strategic direction. | Ticker | | | | | | | | | | | | | | | earnings_transcript | MLAB (ticker) | MLAB_9691d098 | 2026-08-10 |
| Release of full-year fiscal 2027 guidance. | at our next earnings call in November | 2026-11-01 | 2026-11-30 | This will provide critical financial outlook for the company, influencing investor sentiment and valuation. Strong guidance would be bullish, while weak guidance would be bearish. | Ticker | | | | | | | | | | | | | | | earnings_transcript | MLAB (ticker) | MLAB_c132583c | 2026-08-10 |
| Accessing the next $10 million tranche under the debt facility with Trinity Capital. | later this year | 2026-10-01 | 2026-12-31 | This provides crucial additional liquidity, supporting the company's financial stability and pathway to positive cash flow. | Ticker | | | | | | | | | | | | | | | earnings_transcript | RPID (ticker) | RPID_e535f265 | 2026-08-07 |
| MilliporeSigma's contribution to Rapid Micro Biosystems' system placements in 2026, and whether they satisfy their full year 2 system commitment. | 2026 system placements, with some potentially placed in Q1 2027 | 2026-01-01 | 2027-03-31 | The partnership is expected to meaningfully contribute to system placements and broaden global reach. The extent of this contribution will directly impact revenue and growth targets for 2026. | Ticker | | | | | | | | | | | | | | | earnings_transcript | RPID (ticker) | RPID_3ef2524b | 2026-03-12 |
| Completion of at least 25 validations of Growth Direct systems in 2026, including those from large multisystem orders like Amgen and Samsung Biologics. | at least 25 validations in 2026 | 2026-01-01 | 2026-12-31 | Validations are critical for systems to become fully operational and start generating recurring consumable revenue. A faster validation pace can accelerate recurring revenue growth and improve service margins. | Ticker | | | | | | | | | | | | | | | earnings_transcript | RPID (ticker) | RPID_20ea1368 | 2026-03-12 |
| Release of Rapid Micro Biosystems' next-generation cloud-native software platform, leveraging AI-driven analytics and insights. | second half of 2026 | 2026-07-01 | 2026-12-31 | This new platform could redefine the Growth Direct experience, provide significant additional value to customers, and potentially open new avenues for high-margin recurring revenue, impacting long-term growth and valuation. | Ticker | | | | | | | | | | | | | | | earnings_transcript | RPID (ticker) | RPID_600f7b72 | 2026-03-12 |
| Rapid Micro Biosystems discussing and potentially securing new collaboration opportunities with Samsung Biologics beyond the current Growth Direct system deployment. | in the quarters and years ahead | 2026-04-01 | 2028-03-12 | Expanding the partnership with a major CDMO like Samsung Biologics could lead to new revenue streams, broader market penetration, and enhanced credibility, positively impacting long-term growth prospects. | Ticker | | | | | | | | | | | | | | | earnings_transcript | RPID (ticker) | RPID_331042b0 | 2026-03-12 |
| Achievement of net leverage ratio in the range of 1.5x to 1.75x. | as we exit this fiscal year | 2027-01-01 | 2027-03-31 | Reaching this target demonstrates strong balance sheet management and financial flexibility, which is a key strategic priority for the new CEO. This would be a bullish signal. | Ticker | | | | | | | | | | | | | | | earnings_transcript | MLAB (ticker) | MLAB_16eed91f | 2026-08-10 |